Navigation Links
GeoVax Labs Presents New Findings on Potential HIV Vaccine at 2012 Conference on Retroviruses and Opportunistic Infections (CROI)
Date:3/7/2012

tory and clinical research into progress against the AIDS epidemic. Over 4,000 leading researchers and clinicians from around the world convene in a different location each year for the conference.

The first generation GeoVax vaccine that does not co-express GM-CSF has shown excellent safety and reproducible vaccine responses in Phase 1 and Phase 2a clinical trials in over 400 uninfected people. These trials, supported and conducted by the U.S. National Institutes of Health HIV Vaccine Trials Network, set the stage for the 2nd generation GM-CSF co-expressing vaccine to move from its initial Phase 1 safety testing (slated to start in March of this year) to a Phase 2b efficacy trial in participants who are at high risk of exposure to HIV. The vaccine is designed for the "clade B" version of the HIV virus prevalent in the Americas. Since 1989, the United States, despite education and availability of drugs, has consistently suffered about 55,000 new infections per year. And according to a 2010 study by the U.S. Centers for Disease Control (CDC), of those individuals in the United States who are diagnosed with HIV, only 35% ultimately achieve viral load suppression through drug treatment. Thus, there is an obvious need for therapies to complement drug treatment.

About GeoVax Labs, Inc.
GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV. Our goals include developing HIV/AIDS vaccines for global markets, overseeing the manufacture and testing of these vaccines under GMP/GLP conditions (FDA guidelines), conducting clinical trials for vaccine safety and effectiveness, and obtaining regulatory approvals to move the product forward. GeoVax's vaccines are unique in expressing virus like particles that display the trimeric membrane bound form of the HIV-1 envelope glycoprotein. All preventative Phase 1 human clinical trials conducted to date tested various combinations and doses of our DNA and MVA vaccines, thei
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
2. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
3. GeoVax Presents Data at AIDS Vaccine 2008 Conference
4. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
5. GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
6. GeoVax to Present at the BIO CEO & Investor Conference 2009
7. GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference
8. GeoVax Update Provided at the BIO CEO & Investor Conference 2009
9. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results
10. GeoVax Labs, Inc. Announces First Quarter Financial Results
11. GeoVax to Exhibit at the 2009 BIO International Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/p2ddnr/global_market ) ... of Trypsin" report to their offering. , ... providing comprehensive data on Trypsin globally and regionally ( ... North America , Latin America ... Trypsin This report focuses on three primary areas; ...
(Date:2/27/2015)... Feb. 27, 2015  Pfenex Inc. (NYSE MKT: PFNX), ... biosimilar therapeutics, today announced that it will be presenting ... on March 2 nd at 3pm PST. Patrick Lucy, ... panel discussing the current state of the biosimilar industry ... For more information on CALBIO 2015 ...
(Date:2/27/2015)... BOSTON , Feb. 27, 2015   PureTech ... identifying, inventing and commercializing disruptive products and technologies in ... Christopher Viehbacher , former CEO and Member of the ... Directors.  "It,s has been a pleasure ... very excited that we will be working together more ...
(Date:2/26/2015)... 26, 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or ... company that develops and commercializes proprietary technologies and products ... operational results for the fiscal first quarter ended December ... in Canadian dollars (CAD), unless otherwise stated. ... new business from our existing customers and add to ...
Breaking Biology Technology:Global Market Report of Trypsin 2014-2018 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4SQI Diagnostics Reports First Quarter Financial Results 2SQI Diagnostics Reports First Quarter Financial Results 3SQI Diagnostics Reports First Quarter Financial Results 4SQI Diagnostics Reports First Quarter Financial Results 5SQI Diagnostics Reports First Quarter Financial Results 6
... Horizon Therapeutics, Inc., a,privately held biopharmaceutical company, announced ... officer, will present a corporate,overview at the JMP ... October 7 at 9 a.m. ET at the ... Horizon Therapeutics, Inc. is a late-stage biopharmaceutical ...
... N.J., Oct. 1 SyntheMed, Inc. (OTC,Bulletin Board: ... commercialization of anti-adhesion products and other surgical,implants, announced ... of a,private placement in which it received $4.0 ... the issuance to investors of ten million units,at ...
... Halozyme Therapeutics, Inc.,(Nasdaq: HALO ), a ... matrix, today announced that it will,host a Research ... p.m. EDT. A,webcast of the presentations will be ... -- Strategic Company Overview, Jonathan Lim, M.D., ...
Cached Biology Technology:SyntheMed Completes $4.0 Million Equity Placement 2Halozyme Therapeutics to Host Research Day for Investors and Analysts 2
(Date:2/24/2015)... NEW YORK , Feb. 24, 2015 This report ... Thousands by the following Segments: Face Biometrics, and Voice Biometrics. The ... , Japan , Europe ... & Africa , and Latin ... period 2013 through 2020. Also, a seven-year historic analysis is provided ...
(Date:2/13/2015)... TAIPEI , Feb. 13, 2015 ... service company that aims to transform cancer genomic ... announced that the company has raised US$ 8 million ... Based in Taipei, Taiwan ... tests, ACTDrug™, ACTOnco™. With the aim to implement ...
(Date:2/9/2015)... , Feb. 9, 2015  Lintec of America ... methods for carbon nanotube (CNT) macrostructures, including sheets, yarns ... Dallas (UTD). Leveraging the vast industrial resources ... Tokyo, Japan , Lintec of America is forming ... Richardson, TX , focusing on scaling up the ...
Breaking Biology News(10 mins):World Face and Voice Biometrics Industry 2World Face and Voice Biometrics Industry 3World Face and Voice Biometrics Industry 4World Face and Voice Biometrics Industry 5World Face and Voice Biometrics Industry 6World Face and Voice Biometrics Industry 7World Face and Voice Biometrics Industry 8World Face and Voice Biometrics Industry 9World Face and Voice Biometrics Industry 10World Face and Voice Biometrics Industry 11World Face and Voice Biometrics Industry 12World Face and Voice Biometrics Industry 13World Face and Voice Biometrics Industry 14World Face and Voice Biometrics Industry 15World Face and Voice Biometrics Industry 16ACT Genomics Raises $8 Million in its First Private Funding Round 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4
... the chemical marks littering the DNA inside our cells like ... at a time. But new high-throughput DNA sequencing technology has ... map the precise position of these individual DNA modifications throughout ... effect on the activity of any of Arabidopsis roughly 26,000 ...
... have struggled with plutonium contamination spreading further in groundwater ... and animals. It was known nanometer sized clusters ... had been able to study its structure or find ... Scientists at the U.S. Department of Energys Argonne ...
... scientists have uncovered details about the mechanisms through which ... cells, the researchers have linked ribosomes, the protein-making factories ... aids in the expression of genetic information, to the ... which was led by UW faculty members Brian Kennedy ...
Cached Biology News:Charting the epigenome 2Charting the epigenome 3Scientists discover how nanocluster contaminants increase risk of spreading 2Researchers uncover details about how dietary restriction slows down aging 2Researchers uncover details about how dietary restriction slows down aging 3
... cytoplasmic granules, is a key step ... (e.g. basophils, neutrophils, eosinophils, and mast ... secretory granules contain many proinflammatory mediators ... proteases (Hallgren, 2001). Tryptase, a tetrameric ...
... Custom Processing Service enables scientists who do not ... analysis software to have their biological samples tested ... Its as easy as 1-2-3 Chose ... your samples from the S&S antibody menu. ...
... sensitive nucleic acid gel stain has bright fluorescence ... gels, making it ideal for detecting dsDNA in ... SYBR Green I nucleic gel acid stain ... real-time PCR assays and bandshift assays. One mL ...
... Todays advanced protein cross-linking techniques are defined ... Dr. Shan S. Wong. This valuable hardcover ... schemes and current application references. More than ... protein cross-linking and conjugate preparation from ...
Biology Products: